United States Department of Transportation
i
Narcolepsy (with and without Cataplexy) and Commercial Motor Vehicle Driver Safety
-
2009-10-01
[PDF-2.91 MB]
Details:
-
Creators:
-
Corporate Creators:
-
Subject/TRT Terms:
-
DOI:
-
Resource Type:
-
Geographical Coverage:
-
Corporate Publisher:
-
Abstract:The purpose of this evidence report is to address several questions posed by FMCSA regarding the topic of narcolepsy and commercial motor vehicle (CMV) driver safety. In the early scope development work conducted by the Agency and the Medical Review Board (MRB), the following issues of concern were raised: 1. Does narcolepsy result in an increased risk of CMV crash? Does narcolepsy result in an increased risk of personal vehicle crash? 2. Is there experimental evidence that narcolepsy results in driving impairment (e.g., driving simulator studies)? 3. Is there quality evidence that treatment of narcolepsy reduces risk of crash to that of the appropriately certified CMV driving population? Is there quality evidence that treatment of narcolepsy reduces risk of personal vehicle crashes to that of the healthy general driving population? 4. Does use of modafinil to treat narcolepsy reduce risk of crash to that of the appropriately certified CMV driving population? Does use of modafinil for treatment of narcolepsy reduce risk of personal vehicle crash to that of the healthy general driving population?
-
Format:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
